{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:35:41Z","timestamp":1784309741595,"version":"3.55.0"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[1998,3,1]],"date-time":"1998-03-01T00:00:00Z","timestamp":888710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    CS-834 is a prodrug of the carbapenem R-95867, developed by Sankyo Co., Ltd., Tokyo, Japan. To investigate the possibility that CS-834 may be the first carbapenem usable in an oral dosage form, its in vitro antibacterial activity (as R-95867) and in vivo antibacterial activity were compared with those of cefpodoxime proxetil, cefditoren pivoxil, cefdinir, ofloxacin, imipenem, and amoxicillin. R-95867 had high levels of activity against methicillin-susceptible staphylococci and streptococci, including penicillin-resistant\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    , as well as\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    ,\n                    <jats:italic>Moraxella catarrhalis<\/jats:italic>\n                    , the members of the family\n                    <jats:italic>Enterobacteriaceae<\/jats:italic>\n                    (with the exception of\n                    <jats:italic>Serratia marcescens<\/jats:italic>\n                    ),\n                    <jats:italic>Haemophilus influenzae<\/jats:italic>\n                    , and\n                    <jats:italic>Bordetella pertussis<\/jats:italic>\n                    ; for all these strains, the MICs at which 90% of tested strains are inhibited (MIC\n                    <jats:sub>90<\/jats:sub>\n                    s) were 1.0 \u03bcg\/ml or less. Against methicillin-resistant staphylococci, enterococci,\n                    <jats:italic>Serratia marcescens<\/jats:italic>\n                    ,\n                    <jats:italic>Brukholderia cepacia<\/jats:italic>\n                    ,\n                    <jats:italic>Stenotrophomonas maltophilia<\/jats:italic>\n                    , and\n                    <jats:italic>Acinetobacter calcoaceticus<\/jats:italic>\n                    , R-95867 showed activity comparable to or slightly less than that of imipenem, with MIC\n                    <jats:sub>90<\/jats:sub>\n                    s ranging from 2 to &gt;128 \u03bcg\/ml. The in vivo efficacy of oral CS-834 against experimental mouse septicemia caused by gram-positive and gram-negative bacteria was better than that of comparative drugs. In murine respiratory infection models, the efficacy of CS-834 reflected not only its potent in vitro activity but also the high levels present in the lungs.\n                  <\/jats:p>","DOI":"10.1128\/aac.42.3.555","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T20:30:35Z","timestamp":1539030635000},"page":"555-563","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["In Vitro and In Vivo Antibacterial Activities of CS-834, a New Oral Carbapenem"],"prefix":"10.1128","volume":"42","author":[{"given":"Keizo","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Domon","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ohno","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Furuya","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, Toho University School of Medicine, Omori-nishi, 5-21-16, Ota-ku, Tokyo 143, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1030"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7164\/antibiotics.44.338","article-title":"6-(Substituted methylene) penems, potent broad spectrum inhibitors of bacterial beta-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives.","volume":"44","author":"Bennett I.","year":"1991","unstructured":"Bennett I. Broom N. Coleman K. Coulton S. Edwards P. Fracois I. Griffin D. Osborne N. Woodall P. 6-(Substituted methylene) penems, potent broad spectrum inhibitors of bacterial beta-lactamase. IV. Kidney stability, serum binding and additional biological evaluation of racemic derivatives. J. Antibiot. 44 1991 338 343","journal-title":"J. Antibiot."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1413"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.7.1577"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.25.2.179","article-title":"Stimulation of granulocyte functions in vitro by imipenem and the renal enzyme inhibitor MK 0791.","volume":"25","author":"Gnarpe H.","year":"1984","unstructured":"Gnarpe H. Belsheim J. Blomqvist C. Lundback A. Stimulation of granulocyte functions in vitro by imipenem and the renal enzyme inhibitor MK 0791. Antimicrob. Agents Chemother. 25 1984 178 181","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/30.2.129","article-title":"Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex.","volume":"30","author":"Hikida M.","year":"1992","unstructured":"Hikida M. Kawashima K. Yoshida M. Mitsuhashi S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 30 1992 129 134","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2269"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06792.x"},{"key":"e_1_3_2_10_2","first-page":"102","article-title":"Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by microdilution method.","volume":"38","author":"Japanese Society for Chemotherapy","year":"1990","unstructured":"Japanese Society for Chemotherapy Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by microdilution method. Chemotherapy (Tokyo) 38 1990 102 105","journal-title":"Chemotherapy (Tokyo)"},{"key":"e_1_3_2_11_2","first-page":"183","article-title":"Method for the determination of minimum inhibitory concentration (MIC) of fastidious bacteria and anaerobic bacteria by microdilution method.","volume":"41","author":"Japanese Society for Chemotherapy","year":"1993","unstructured":"Japanese Society for Chemotherapy Method for the determination of minimum inhibitory concentration (MIC) of fastidious bacteria and anaerobic bacteria by microdilution method. Chemotherapy (Tokyo) 41 1993 183 189","journal-title":"Chemotherapy (Tokyo)"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7164\/antibiotics.50.429","article-title":"Synthesis and structure-activity relationships of a novel oral carbapenem, CS-834, J.","volume":"50","author":"Miyauchi M.","year":"1997","unstructured":"Miyauchi M. Endo R. Hisaoka M. Yasuda H. Kawamoto I. Synthesis and structure-activity relationships of a novel oral carbapenem, CS-834, J. Antibiot. 50 1997 429 439","journal-title":"Antibiot."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.1.205"},{"key":"e_1_3_2_14_2","unstructured":"Nakashima M. Umemura K. Ikeda Y. Kondou K. CS-834 a new oral carbapenem. V. Safety and pharmacokinetics in healthy male volunteer abstr. F109 Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996 119 American Society for Microbiology Washington D.C"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev.mi.41.100187.003041","article-title":"Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics.","volume":"41","author":"Sanders C.","year":"1987","unstructured":"Sanders C. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics. Annu. Rev. Microbiol. 41 1987 573 593","journal-title":"Annu. Rev. Microbiol."},{"key":"e_1_3_2_16_2","first-page":"241","article-title":"Overview of a new carbapenem, panipenem\/betamipron.","volume":"20","author":"Shimada J.","year":"1994","unstructured":"Shimada J. Kawahara Y. Overview of a new carbapenem, panipenem\/betamipron. Drugs Exp. Clin. Res. 20 1994 241 245","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-45-5-319"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0090-9556(25)07613-5","article-title":"Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.","volume":"18","author":"Tsuji A.","year":"1990","unstructured":"Tsuji A. Sato H. Tamai I. Adachi H. Nishihara T. Ishiguro M. Ohmura N. Noguchi T. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. Drug Metab. Dispos. 18 1990 245 252","journal-title":"Drug Metab. Dispos."}],"updated-by":[{"DOI":"10.1128\/aac.42.6.1527","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.3.555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.3.555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:01:17Z","timestamp":1775242877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.3.555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1128\/AAC.42.3.555"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.3.555","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]},"assertion":[{"value":"1997-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}